Amgen NSCLC Data Could Give Lumakras Boost As Competition Looms

Amgen, Inc. KRAS inhibitor Lumakras (sotorasib)’s market position stands to gain from two-year follow-up data from the company’s pivotal study in non-small cell lung cancer showing continued benefit on survival. Longer-term survival data could help bolster Amgen’s commercial case for its drug as it gears up for potentially stiff competition from Mirati Therapeutics, Inc.’s adagrasib, a competing drug in the same class that is widely expected to get US Food and Drug Administration approval and has shown better data than Lumakras in two other key KRAS-mutated cancers.

Amgen presented two-year follow-up data from the Phase I/II CodeBreaK 100 study in patients with KRAS G12C-mutated advanced non-small cell...